W Strategies, LLC Government Affairs Consulting Firm. 1455 Pennsylvania Avenue, NW Suite 400 Washington, DC 20004 USA |
Lobbying on the following issues:
MEDICARE/MEDICAID HEALTH ISSUES Education about reimbursement for orphan drug therapies in skilled nursing facilities and proposed add-on payments in inpatient hospitals. - Education about the value of innovative new medicines and the Orphan Drug Act. - Lobbyists: WILLCOX, DARREN
Foreign Entities: Foreign Entity Name: CACIFCountry : GUATEMALAContribution : $30,000 |
Lobbying on the following issues:
HEALTH ISSUES Issues related to vaping products, including education about the value of these products in harm reduction. Education about the companys efforts to reduce youth access to vaping products as well as FDA proposals in this area. - Lobbyists: WILLCOX, DARREN
Foreign Entities: Foreign Entity Name: CACIFCountry : GUATEMALAContribution : $30,000 |
Lobbying on the following issues:
HEALTH ISSUES MEDICARE/MEDICAID Education about the 340(b) drug discount program. - Education on the importance of maintaining the competitive elements of the Part D prescription drug program and to oppose efforts to impose mandatory government rebates in that program and concerns about beneficiary out of pocket costs. H.R.1892: Bipartisan Budget Act 2018 as it relates to a Part D donut hole provision. H.R.7217: ACE Kids Act. H.R.6642: To amend title XIX of the Social Security Act to sunset the limit on the maximum rebate amount for single source drugs and innovator multiple source drugs. - Lobbyists: WILLCOX, DARREN
Foreign Entities: Foreign Entity Name: CACIFCountry : GUATEMALAContribution : $30,000 |
Lobbying on the following issues:
HEALTH ISSUES MEDICARE/MEDICAID Education about the value of innovative new medicines and the Orphan Drug Act. - Education about reimbursement for orphan drug therapies in skilled nursing facilities and proposed add-on payments in inpatient hospitals. - Lobbyists: WILLCOX, DARREN
Foreign Entities: Foreign Entity Name: Samil Spinning Co., LtdCountry : NORTH KOREAContribution : $0 |
Lobbying on the following issues:
MEDICARE/MEDICAID Education about CMS rule changing protections for beneficiaries in Medicare Part D six protected classes. - Lobbyists: WILLCOX, DARREN
Foreign Entities: Foreign Entity Name: Samil Spinning Co., LtdCountry : NORTH KOREAContribution : $0 |
Lobbying on the following issues:
HEALTH ISSUES Issues related to vaping products, including education about the value of these products in harm reduction. Education about the companys efforts to reduced youth access to vaping products as well as FDA proposals in this area. Advocating for legislation to create a federal age 21 requirement for all nicotine products. - Lobbyists: WILLCOX, DARREN
Foreign Entities: Foreign Entity Name: Samil Spinning Co., LtdCountry : NORTH KOREAContribution : $0 |
Lobbying on the following issues:
HEALTH ISSUES MEDICARE/MEDICAID H.R. 965: CREATES Act. - Education on the importance of maintaining the competitive elements of the Part D prescription drug program and to oppose efforts to impose mandatory government rebates in that program and concerns about beneficiary out of pocket costs. H.R. 107: To amend title XIX of the Social Security Act to sunset the limit on the maximum rebate amount for single source drugs and innovator multiple source drugs. Regulatory and legislative proposals in the Administrations Drug Pricing Blueprint - Lobbyists: WILLCOX, DARREN
Foreign Entities: Foreign Entity Name: Samil Spinning Co., LtdCountry : NORTH KOREAContribution : $0 |
Lobbying on the following issues:
MEDICARE/MEDICAID HEALTH ISSUES Education about reimbursement for orphan drug therapies in skilled nursing facilities and proposed add-on payments in inpatient hospitals. H.R.2113: Prescription Drug STAR Act. - Education about the value of innovative new medicines and the Orphan Drug Act. S.: Lower Health Care Costs Act of 2019. - Lobbyists: WILLCOX, DARREN
|
Lobbying on the following issues:
MEDICARE/MEDICAID HEALTH ISSUES Education about CMS rule changing protections for beneficiaries in Medicare Part D six protected classes. Regulatory and legislative proposals in the Administrations Drug Pricing Blueprint. - Education around access to HIV therapies. - Lobbyists: WILLCOX, DARREN
|
Lobbying on the following issues:
TOBACCO Issues related to vaping products, including education about the value of these products in harm reduction. Education about the companys efforts to reduced youth access to vaping products as well as FDA proposals in this area. Education about counterfeit product detection and prevention with vapor products. S.1541: Tobacco-Free Youth Act. S.1258: Tobacco to 21 Act. - Lobbyists: WILLCOX, DARREN
|
Lobbying on the following issues:
MEDICARE/MEDICAID Education on the importance of maintaining the competitive elements of the Part D prescription drug program and to oppose efforts to impose mandatory government rebates in that program and concerns about beneficiary out of pocket costs. H.R.107: To amend title XIX of the Social Security Act to sunset the limit on the maximum rebate amount for single source drugs and innovator multiple source drugs. H.R.2113: Prescription Drug STAR Act. H.R.2069: SPIKE Act. H.R.2296: FAIR Drug Pricing Act of 2019. Regulatory and legislative proposals in the Administrations Drug Pricing Blueprint. CMS rule dealing with Removal of Safe Harbor Protection for Rebates Involving Prescription Pharmaceuticals. - Lobbyists: WILLCOX, DARREN
|
Lobbying on the following issues:
HEALTH ISSUES MEDICARE/MEDICAID Education about the value of innovative new medicines and the Orphan Drug Act. - S.2543: Prescription Drug Pricing Reduction Act of 2019. Regulatory and legislative proposals in the Administration's Rx Blueprint. H.R.3: Lower Drug Costs Now Act of 2019. - Lobbyists: WILLCOX, DARREN
Foreign Entities: Foreign Entity Name : Roivant Sciences Ltd.Country : BERMUDAContribution : $0 - Foreign Entity Name : Roivant Sciences Holdings Ltd.Country : UNITED KINGDOMContribution : $0 - |
Lobbying on the following issues:
MEDICARE/MEDICAID HEALTH ISSUES Regulator and legislative proposals in the Administration's Drug Pricing Blueprint. H.R.3: Lower Drug Costs Now Act of 2019. S.2543: Prescription Drug Pricing Reduction Act of 2019. - Education around access to HIV therapies. - Lobbyists: WILLCOX, DARREN
Foreign Entities: Foreign Entity Name : Roivant Sciences Ltd.Country : BERMUDAContribution : $0 - Foreign Entity Name : Roivant Sciences Holdings Ltd.Country : UNITED KINGDOMContribution : $0 - |
Lobbying on the following issues:
TOBACCO Education about the companys efforts to reduced youth access to vaping products as well as FDA proposals in this area. Education about counterfeit product detection and prevention with vapor products. S.1541: Tobacco-Free Youth Act. S.1258: Tobacco to 21 Act. - Lobbyists: WILLCOX, DARREN
Foreign Entities: Foreign Entity Name : LVMH Moet Hennessy Louis Vuitton Inc.Country : FRANCEContribution : $0 - Foreign Entity Name : Sofidiv S.A.S.Country : FRANCEContribution : $0 - |
Lobbying on the following issues:
MEDICARE/MEDICAID Education on the importance of maintaining the competitive elements of the Part D prescription drug program and to oppose efforts to impose mandatory government rebates in that program and concerns about beneficiary out of pocket costs. H.R.107: To amend title XIX of the Social Security Act to sunset the limit on the maximum rebate amount for single source drugs and innovator multiple source drugs. Regulatory and legislative proposals in the Administrations Drug Pricing Blueprint. CMS rule dealing with Removal of Safe Harbor Protection for Rebates Involving Prescription Pharmaceuticals. H.R.3: Lower Drug Costs Now Act of 2019. S.2543: Prescription Drug Pricing Reduction Act of 2019. - Lobbyists: WILLCOX, DARREN
Foreign Entities: Foreign Entity Name : LVMH Moet Hennessy Louis Vuitton Inc.Country : FRANCEContribution : $0 - Foreign Entity Name : Sofidiv S.A.S.Country : FRANCEContribution : $0 - |
Lobbying on the following issues:
MEDICARE/MEDICAID HEALTH ISSUES Regulatory and legislative proposals in the Administration's Rx Blueprint. H.R.3: Lower Drug Costs Now Act of 2019. - H.R.4378: Continuing Appropriations Act, 2020, and Health Extenders Act of 2019. - Lobbyists: WILLCOX, DARREN
Foreign Entities: Foreign Entity Name : Roivant Sciences Ltd.Country : BERMUDAContribution : $0 - Foreign Entity Name : Roivant Sciences GmbHCountry : SWITZERLANDContribution : $0 - Foreign Entity Name : Roivant Sciences Holdings Ltd.Country : UNITED KINGDOMContribution : $0 - |
Lobbying on the following issues:
MEDICARE/MEDICAID HEALTH ISSUES Regulatory and legislative proposals in the Administration's Drug Pricing Blueprint. H.R.3: Lower Drug Costs Now Act of 2019. H.R.19: Lower Costs, More Cures Act of 2019. S.2543: Prescription Drug Pricing Reduction Act of 2019. - Education around access to HIV therapies. - Lobbyists: WILLCOX, DARREN
Foreign Entities: Foreign Entity Name : Roivant Sciences Ltd.Country : BERMUDAContribution : $0 - Foreign Entity Name : Roivant Sciences GmbHCountry : SWITZERLANDContribution : $0 - Foreign Entity Name : Roivant Sciences Holdings Ltd.Country : UNITED KINGDOMContribution : $0 - |
Lobbying on the following issues:
TAXATION/INTERNAL REVENUE CODE TOBACCO H.R.4742: Impose Tax on Nicotine Used in Vaping Products. - Education about the companys efforts to reduced youth access to vaping products as well as FDA proposals in this area. Education about counterfeit product detection and prevention with vapor products. S.1541: Tobacco-Free Youth Act. S.1258: Tobacco to 21 Act. H.R. 2339: Reversing the Youth Tobacco Epidemic Act of 2019. - Lobbyists: WILLCOX, DARREN
Foreign Entities: Foreign Entity Name : Roivant Sciences Ltd.Country : BERMUDAContribution : $0 - Foreign Entity Name : Roivant Sciences GmbHCountry : SWITZERLANDContribution : $0 - Foreign Entity Name : Roivant Sciences Holdings Ltd.Country : UNITED KINGDOMContribution : $0 - |
Lobbying on the following issues:
MEDICARE/MEDICAID TRADE (DOMESTIC/FOREIGN) H.R.107: To amend title XIX of the Social Security Act to sunset the limit on the maximum rebate amount for single source drugs and innovator multiple source drugs. Regulatory and legislative proposals in the Administrations Drug Pricing Blueprint. H.R.3: Lower Drug Costs Now Act of 2019. H.R.19: Lower Costs, More Cures Act of 2019. S.2543: Prescription Drug Pricing Reduction Act of 2019. - United States-Mexico-Canada Agreement (USMCA). - Lobbyists: WILLCOX, DARREN
Foreign Entities: Foreign Entity Name : Roivant Sciences Ltd.Country : BERMUDAContribution : $0 - Foreign Entity Name : Roivant Sciences GmbHCountry : SWITZERLANDContribution : $0 - Foreign Entity Name : Roivant Sciences Holdings Ltd.Country : UNITED KINGDOMContribution : $0 - |
Lobbying on the following issues:
HEALTH ISSUES H.R.4712: Fairness in Orphan Drug Exclusivity Act. - Lobbyists: WILLCOX, DARREN
|
Lobbying on the following issues:
MEDICARE/MEDICAID H.R.107: to sunset the limit on maximum rebate amount for single source drugs. H.R.3: Lower Drug Costs Now Act of 2019. H.R.19: Lower Costs, More Cures Act of 2019. Regulatory and legislative proposals in the Administrations Blueprint. - Lobbyists: WILLCOX, DARREN
|
Lobbying on the following issues:
MEDICARE/MEDICAID HEALTH ISSUES Regulatory and legislative proposals in the Administration's Drug Pricing Blueprint. H.R.3: Lower Drug Costs Now Act of 2019. H.R.19: Lower Costs, More Cures Act of 2019. S.2543: Prescription Drug Pricing Reduction Act of 2019. - Issues related to potential therapies for COVID-19. - Lobbyists: WILLCOX, DARREN
|
Lobbying on the following issues:
MEDICARE/MEDICAID PHARMACY H.R.107: To amend title XIX of the Social Security Act to sunset the limit on the maximum rebate amount for single source drugs and innovator multiple source drugs. Regulatory and legislative proposals in the Administrations Drug Pricing Blueprint. H.R.3: Lower Drug Costs Now Act of 2019. H.R.19: Lower Costs, More Cures Act of 2019. S.2543: Prescription Drug Pricing Reduction Act of 2019. FY 2021 Notice of Benefits and Payment Parameters Proposed Rule. - H.R.4710 - Pharmaceutical Independence Long-Term Readiness Reform Act. - Lobbyists: WILLCOX, DARREN
Foreign Entities: Foreign Entity Name : Canadian NationalCountry : CANADAContribution : $122,024 - Foreign Entity Name : Canadian PacificCountry : CANADAContribution : $0 - |
Lobbying on the following issues:
TAXATION/INTERNAL REVENUE CODE TOBACCO H.R.4742: Impose Tax on Nicotine Used in Vaping Products. - Education about the companys efforts to reduced youth access to vaping products as well as FDA proposals in this area. Education about counterfeit product detection and prevention with vapor products. H.R. 2339: Reversing the Youth Tobacco Epidemic Act of 2019. - Lobbyists: WILLCOX, DARREN
Foreign Entities: Foreign Entity Name: ANA Holdings, IncCountry : JAPANContribution : $50,000 |
Lobbying on the following issues:
TRADE (DOMESTIC/FOREIGN) TAXATION/INTERNAL REVENUE CODE MEDICARE/MEDICAID HEALTH ISSUES Education about medical device coverage and reimbursement issues in Japan. - H.R.4617: Protect Medical Innovation Act and H.R.88 as it relates to the medical device tax. - Education about the implementation of PAMA with respect to physician office labs. - Development of legislation regulated to regulation of LDT's, including a discussion draft of Diagnostic Accuracy and Improvement Act. - Lobbyists: WILLCOX, DARREN
Foreign Entities: Foreign Entity Name: CACIFCountry : GUATEMALAContribution : $30,000 |
Lobbying on the following issues:
HEALTH ISSUES MEDICARE/MEDICAID Education about the 340(b) drug discount program. H.R.4710: 340(b) PAUSE Act. H.R.5598: 340B Optimization Act. - H.R.7217: IMPROVE Act. - Lobbyists: WILLCOX, DARREN
Foreign Entities: Foreign Entity Name: CACIFCountry : GUATEMALAContribution : $30,000 |
Lobbying on the following issues:
MEDICARE/MEDICAID BUDGET/APPROPRIATIONS HEALTH ISSUES H.R.6642: "to sunset the limit on maximum rebate amount for single source drugs". - H.R.1892: Bipartisan Budget Act of 2018 as it relates to a Part D donut hole provision. - Education about innovative contracting and value based payments. Education about the 340(b) drug discount program including the CMS 340(b) CMP Rule. - Lobbyists: WILLCOX, DARREN
Foreign Entities: Foreign Entity Name: CACIFCountry : GUATEMALAContribution : $30,000 |
Lobbying on the following issues:
HEALTH ISSUES FY 2019 Labor/HHS appropriations bill as it relates to funding for newborn screening. Education about the RUSP (Recommended Uniform Screening Panel) as it relates to SMA. - Lobbyists: WILLCOX, DARREN
Foreign Entities: Foreign Entity Name: CACIFCountry : GUATEMALAContribution : $30,000 |
Lobbying on the following issues:
BUDGET/APPROPRIATIONS HEALTH ISSUES MEDICARE/MEDICAID H.R.1892: Bipartisan Budget Act of 2018 as it relates to a Part D coverage gap provision. - H.R.6378/S.2852: Reauthorization of the Pandemic All-Hazards Preparedness Act (PAHPA). - H.R.6642: "to sunset the limit on the maximum rebate amount for single source drugs". - Lobbyists: WILLCOX, DARREN
Foreign Entities: Foreign Entity Name: CACIFCountry : GUATEMALAContribution : $30,000 |
Lobbying on the following issues:
HEALTH ISSUES Education and awareness of mental health issues especially as it relates to postpartum depression. - Lobbyists: WILLCOX, DARREN
Foreign Entities: Foreign Entity Name: CACIFCountry : GUATEMALAContribution : $30,000 |
Lobbying on the following issues:
HEALTH ISSUES BUDGET/APPROPRIATIONS H.R.6378/S.2852: Reauthorization of the Pandemic All-Hazards Preparedness Act (PAHPA). H.R.5333: Over-the-Counter Monograph Safety, Innovation, and Reform Act of 2018. - H.R.1892: Bipartisan Budget Act of 2018 as it relates to a Part D coverage gap provision. - Lobbyists: WILLCOX, DARREN
|
Lobbying on the following issues:
TAXATION/INTERNAL REVENUE CODE HEALTH ISSUES MEDICARE/MEDICAID DEFENSE H.R. 2207: Protect Medical Innovation Act. - Development of legislation regulated to regulation of LDTs, including a discussion draft of VALID Act. - Education about the implementation of PAMA with respect to physician office labs. - FY 2020 NDAA - education about CGM coverage in TRICARE. - Lobbyists: WILLCOX, DARREN
Foreign Entities: Foreign Entity Name: Samil Spinning Co., LtdCountry : NORTH KOREAContribution : $0 |
Lobbying on the following issues:
MEDICARE/MEDICAID HEALTH ISSUES H.R.259: Medicaid Extenders Act of 2019. Education about out of pocket costs for patients in Medicare Part D. Education about CMS rule changing protections for beneficiaries in Medicare Part D six protected classes. Regulatory and legislative proposals in the Administrations Blueprint. - Education about the 340(b) drug discount program. - Lobbyists: WILLCOX, DARREN
Foreign Entities: Foreign Entity Name: Samil Spinning Co., LtdCountry : NORTH KOREAContribution : $0 |
Lobbying on the following issues:
MEDICARE/MEDICAID HEALTH ISSUES H.R.107: to sunset the limit on maximum rebate amount for single source drugs. Regulatory and legislative proposals in the Administrations Blueprint. - Education about innovative contracting and value based payments. - Lobbyists: WILLCOX, DARREN
Foreign Entities: Foreign Entity Name: Samil Spinning Co., LtdCountry : NORTH KOREAContribution : $0 |
Lobbying on the following issues:
HEALTH ISSUES Education and awareness of mental health issues especially as it relates to postpartum depression. - Lobbyists: WILLCOX, DARREN
|
Lobbying on the following issues:
HEALTH ISSUES H.R. 269: Reauthorization of the Pandemic and All Hazards Preparedness Act (PAHPA) and Over-the-Counter Monograph Safety, Innovation and Reform Act of 2019. Draft legislation on cosmetics regulation at FDA. Education around drug pricing, specifically in the insulin market. Education about the public health value of vaccines. - Lobbyists: WILLCOX, DARREN
|
Lobbying on the following issues:
HEALTH ISSUES Education around access to innovative cancer therapies. - Lobbyists: WILLCOX, DARREN
|
Lobbying on the following issues:
MEDICARE/MEDICAID H.R. 107: to sunset the limit on the maximum rebate amount for single source drugs. Proposed legislative and regulatory changes to Medicare Part B, including items from the Administrations Rx Blueprint. - Lobbyists: WILLCOX, DARREN
Foreign Entities: Foreign Entity Name: Swiss Reinsurance Company LtdCountry : SWITZERLANDContribution : $0 |
Lobbying on the following issues:
HEALTH ISSUES TAXATION/INTERNAL REVENUE CODE MEDICARE/MEDICAID DEFENSE Development of legislation regulated to regulation of LDTs, including a discussion draft of VALID Act. Education about adult malnutrition H.R.2113: Prescription Drug STAR Act. - H.R. 2207: Protect Medical Innovation Act. - Education about the implementation of PAMA with respect to physician office labs. - FY 2020 NDAA - education about CGM coverage in TRICARE. - Lobbyists: WILLCOX, DARREN
|
Lobbying on the following issues:
HEALTH ISSUES MEDICARE/MEDICAID Education about the 340(b) drug discount program. H.R.2113: Prescription Drug STAR Act. S. Lower Health Care Costs Act of 2019. - Education about out of pocket costs for patients in Medicare Part D. Regulatory and legislative proposals in the Administrations Blueprint. - Lobbyists: WILLCOX, DARREN
|
Lobbying on the following issues:
MEDICARE/MEDICAID HEALTH ISSUES H.R.107: to sunset the limit on maximum rebate amount for single source drugs. Regulatory and legislative proposals in the Administrations Blueprint. H.R.2113: Prescription Drug STAR Act. - Education about innovative contracting and value based payments. - Lobbyists: WILLCOX, DARREN
|
Lobbying on the following issues:
MEDICARE/MEDICAID H.R. 107: to sunset the limit on the maximum rebate amount for single source drugs. Proposed legislative and regulatory proposals in the Administrations Rx Blueprint. - Lobbyists: WILLCOX, DARREN
|
Lobbying on the following issues:
HEALTH ISSUES Education and awareness of mental health issues especially as it relates to postpartum depression. - Lobbyists: WILLCOX, DARREN
|
Lobbying on the following issues:
MEDICARE/MEDICAID HEALTH ISSUES H.R.107: To amend title XIX of the Social Security Act to sunset the limit on the maximum rebate amount for single source drugs and innovator multiple source drugs. H.R.2087: Drug Price Transparency Act. H.R.2113: Prescription Drug STAR Act. Regulatory and legislative proposals in the Administrations Drug Pricing Blueprint. - H.R. 269: Reauthorization of the Pandemic and All Hazards Preparedness Act (PAHPA) and Over-the-Counter Monograph Safety, Innovation and Reform Act of 2019. Draft legislation on cosmetics regulation at FDA. Issues around influenza vaccines. - Lobbyists: WILLCOX, DARREN
|
Lobbying on the following issues:
HEALTH ISSUES Education around access to innovative cancer therapies. - Lobbyists: WILLCOX, DARREN
|
Lobbying on the following issues:
HEALTH ISSUES TAXATION/INTERNAL REVENUE CODE DEFENSE Development of legislation regulated to regulation of LDTs, including a discussion draft of VALID Act. H.R.2113: Prescription Drug STAR Act. H.R.2064: Sunshine for Samples Act. - H.R. 2207: Protect Medical Innovation Act. - FY 2020 NDAA - education about CGM coverage in TRICARE. - Lobbyists: WILLCOX, DARREN
Foreign Entities: Foreign Entity Name : Roivant Sciences Ltd.Country : BERMUDAContribution : $0 - Foreign Entity Name : Roivant Sciences Holdings Ltd.Country : UNITED KINGDOMContribution : $0 - |
Lobbying on the following issues:
MEDICARE/MEDICAID HEALTH ISSUES Education about out of pocket costs for patients in Medicare Part D. S.2543: Prescription Drug Pricing Reduction Act of 2019. Regulatory and legislative proposals in the Administrations Rx Blueprint. H.R.3: Lower Drug Costs Now Act of 2019. - Education about the 340(b) drug discount program. - Lobbyists: WILLCOX, DARREN
Foreign Entities: Foreign Entity Name : Roivant Sciences Ltd.Country : BERMUDAContribution : $0 - Foreign Entity Name : Roivant Sciences Holdings Ltd.Country : UNITED KINGDOMContribution : $0 - |
Lobbying on the following issues:
MEDICARE/MEDICAID HEALTH ISSUES H.R.107: to sunset the limit on maximum rebate amount for single source drugs. H.R.3: Lower Drug Costs Now Act of 2019. Regulatory and legislative proposals in the Administrations Blueprint. H.R.2113: Prescription Drug STAR Act / H.R.2296: FAIR Drug Pricing Act. FY 2020 Continuing Resolution. - Education about innovative contracting and value based payments. - Lobbyists: WILLCOX, DARREN
Foreign Entities: Foreign Entity Name : Roivant Sciences Ltd.Country : BERMUDAContribution : $0 - Foreign Entity Name : Roivant Sciences Holdings Ltd.Country : UNITED KINGDOMContribution : $0 - |
Lobbying on the following issues:
MEDICARE/MEDICAID H.R.107: to sunset the limit on the maximum rebate amount for single source drugs. Proposed legislative and regulatory proposals in the Administrations Rx Blueprint. H.R.3: Lower Drug Costs Now Act of 2019. S.2543: Prescription Drug Pricing Reduction Act of 2019. - Lobbyists: WILLCOX, DARREN
Foreign Entities: Foreign Entity Name : LVMH Moet Hennessy Louis Vuitton Inc.Country : FRANCEContribution : $0 - Foreign Entity Name : Sofidiv S.A.S.Country : FRANCEContribution : $0 - |
Lobbying on the following issues:
MEDICARE/MEDICAID HEALTH ISSUES Regulatory and legislative proposals in the Administrations Blueprint. - Education and awareness of mental health issues especially as it relates to postpartum depression. - Lobbyists: WILLCOX, DARREN
Foreign Entities: Foreign Entity Name : LVMH Moet Hennessy Louis Vuitton Inc.Country : FRANCEContribution : $0 - Foreign Entity Name : Sofidiv S.A.S.Country : FRANCEContribution : $0 - |
Lobbying on the following issues:
MEDICARE/MEDICAID HEALTH ISSUES H.R.107: To amend title XIX of the Social Security Act to sunset the limit on the maximum rebate amount for single source drugs and innovator multiple source drugs. Regulatory and legislative proposals in the Administrations Drug Pricing Blueprint. H.R.3: Lower Drug Costs Now Act of 2019. - H.R.3433: Over-the-Counter Monograph Safety, Innovation and Reform Act. Draft legislation on cosmetics regulation at FDA. Issues related to RX/OTC switch Issues around influenza vaccines. - Lobbyists: WILLCOX, DARREN
Foreign Entities: Foreign Entity Name : LVMH Moet Hennessy Louis Vuitton Inc.Country : FRANCEContribution : $0 - Foreign Entity Name : Sofidiv S.A.S.Country : FRANCEContribution : $0 - |
Lobbying on the following issues:
HEALTH ISSUES TAXATION/INTERNAL REVENUE CODE MEDICARE/MEDICAID Development of legislation regulated to regulation of LDTs, including a discussion draft of VALID Act. H.R.2064: Sunshine for Samples Act. - H.R.1864, FY 2020 Appropriations as it relates to H.R.2207: Protect Medical Innovation Act. - Administration Executive Order entitled Protecting and Improving Medicare for Our Nations Seniors. - Lobbyists: WILLCOX, DARREN
Foreign Entities: Foreign Entity Name : Roivant Sciences Ltd.Country : BERMUDAContribution : $0 - Foreign Entity Name : Roivant Sciences GmbHCountry : SWITZERLANDContribution : $0 - Foreign Entity Name : Roivant Sciences Holdings Ltd.Country : UNITED KINGDOMContribution : $0 - |
Lobbying on the following issues:
MEDICARE/MEDICAID HEALTH ISSUES Education about out of pocket costs for patients in Medicare Part D. H.R.3: Lower Drug Costs Now Act of 2019. H.R.19: Lower Costs, More Cures Act of 2019. - Education about the 340(b) drug discount program. - Lobbyists: WILLCOX, DARREN
Foreign Entities: Foreign Entity Name : Roivant Sciences Ltd.Country : BERMUDAContribution : $0 - Foreign Entity Name : Roivant Sciences GmbHCountry : SWITZERLANDContribution : $0 - Foreign Entity Name : Roivant Sciences Holdings Ltd.Country : UNITED KINGDOMContribution : $0 - |
Lobbying on the following issues:
MEDICARE/MEDICAID H.R.107: to sunset the limit on maximum rebate amount for single source drugs. H.R.3: Lower Drug Costs Now Act of 2019. H.R.19: Lower Costs, More Cures Act of 2019. Regulatory and legislative proposals in the Administrations Blueprint. - Lobbyists: WILLCOX, DARREN
Foreign Entities: Foreign Entity Name : Roivant Sciences Ltd.Country : BERMUDAContribution : $0 - Foreign Entity Name : Roivant Sciences GmbHCountry : SWITZERLANDContribution : $0 - Foreign Entity Name : Roivant Sciences Holdings Ltd.Country : UNITED KINGDOMContribution : $0 - |
Lobbying on the following issues:
MEDICARE/MEDICAID H.R.107: to sunset the limit on the maximum rebate amount for single source drugs. Proposed legislative and regulatory proposals in the Administrations Rx Blueprint. H.R.3: Lower Drug Costs Now Act of 2019. H.R.19: Lower Costs, More Cures Act of 2019. - Lobbyists: WILLCOX, DARREN
Foreign Entities: Foreign Entity Name : Roivant Sciences Ltd.Country : BERMUDAContribution : $0 - Foreign Entity Name : Roivant Sciences GmbHCountry : SWITZERLANDContribution : $0 - Foreign Entity Name : Roivant Sciences Holdings Ltd.Country : UNITED KINGDOMContribution : $0 - |
Lobbying on the following issues:
MEDICARE/MEDICAID HEALTH ISSUES Maternal health demonstration project at CMMI. H.R.3: Lower Drug Costs Now Act. H.R.19: Lower Costs, More Cures Act of 2019. - Education and awareness of mental health issues especially as it relates to postpartum depression. - Lobbyists: WILLCOX, DARREN
Foreign Entities: Foreign Entity Name : Roivant Sciences Ltd.Country : BERMUDAContribution : $0 - Foreign Entity Name : Roivant Sciences GmbHCountry : SWITZERLANDContribution : $0 - Foreign Entity Name : Roivant Sciences Holdings Ltd.Country : UNITED KINGDOMContribution : $0 - |
Lobbying on the following issues:
HEALTH ISSUES MEDICARE/MEDICAID H.R.3433: Over-the-Counter Monograph Safety, Innovation and Reform Act. Draft legislation on cosmetics regulation at FDA. Issues related to RX/OTC switch - H.R.107: To amend title XIX of the Social Security Act to sunset the limit on the maximum rebate amount for single source drugs and innovator multiple source drugs. Regulatory and legislative proposals in the Administrations Drug Pricing Blueprint. H.R.3: Lower Drug Costs Now Act of 2019. H.R.19: Lower Costs, More Cures Act of 2019. - Lobbyists: WILLCOX, DARREN
Foreign Entities: Foreign Entity Name : Roivant Sciences Ltd.Country : BERMUDAContribution : $0 - Foreign Entity Name : Roivant Sciences GmbHCountry : SWITZERLANDContribution : $0 - Foreign Entity Name : Roivant Sciences Holdings Ltd.Country : UNITED KINGDOMContribution : $0 - |
Lobbying on the following issues:
MEDICARE/MEDICAID HEALTH ISSUES CMS National Coverage Decision on coverage for transcather mitral valve repair. HHS Transparency in Coverage proposed rule. - H.R.6102: VALID Act of 2020. H.R.2064: Sunshine for Samples Act. H.R.2791: Infant Formula Protection Act of 2019. - Lobbyists: WILLCOX, DARREN
Foreign Entities: Foreign Entity Name: Horizon Pharma PLCCountry : IRELANDContribution : $0 |
Lobbying on the following issues:
HEALTH ISSUES MEDICARE/MEDICAID Education about the 340(b) drug discount program. - Legislative proposals to smooth out of pocket costs for patients in Medicare Part D. FY 2021 Notice of Benefits and Payment Parameters proposed rule. - Lobbyists: WILLCOX, DARREN
|
Lobbying on the following issues:
HEALTH ISSUES MEDICARE/MEDICAID H.R.4100: DISARM Act of 2019. S.3548: Coronavirus Aid, Relief, and Economic Security Act or the CARES Act. - H.R.107: to sunset the limit on the maximum rebate amount for single source drugs. Proposed legislative and regulatory proposals in the Administrations Rx Blueprint. H.R.3: Lower Drug Costs Now Act of 2019. H.R.19: Lower Costs, More Cures Act of 2019. - Lobbyists: WILLCOX, DARREN
Foreign Entities: Foreign Entity Name : Canadian NationalCountry : CANADAContribution : $122,024 - Foreign Entity Name : Canadian PacificCountry : CANADAContribution : $0 - |
Lobbying on the following issues:
HEALTH ISSUES MEDICARE/MEDICAID Education and awareness of mental health issues especially as it relates to access for postpartum depression treatment. - H.R.3: Lower Drug Costs Now Act. H.R.19: Lower Costs, More Cures Act of 2019. - Lobbyists: WILLCOX, DARREN
Foreign Entities: Foreign Entity Name : Canadian NationalCountry : CANADAContribution : $122,024 - Foreign Entity Name : Canadian PacificCountry : CANADAContribution : $0 - |
Lobbying on the following issues:
MEDICARE/MEDICAID HEALTH ISSUES H.R.107: To amend title XIX of the Social Security Act to sunset the limit on the maximum rebate amount for single source drugs and innovator multiple source drugs. Regulatory and legislative proposals in the Administrations Drug Pricing Blueprint. H.R.3: Lower Drug Costs Now Act of 2019. H.R.19: Lower Costs, More Cures Act of 2019. - H.R.748: Coronavirus Aid, Relief, and Economic Security Act or the CARES Act as it relates to H.R.3433: Over-the-Counter Monograph Safety, Innovation and Reform Act, and H.R1922: Restoring Access to Medication Act of 2019. Draft legislation on cosmetics regulation at FDA. Issues related to RX/OTC switch. Education around potential therapies and vaccines for COVID-19. - Lobbyists: WILLCOX, DARREN
Foreign Entities: Foreign Entity Name : Canadian NationalCountry : CANADAContribution : $122,024 - Foreign Entity Name : Canadian PacificCountry : CANADAContribution : $0 - |
Lobbying on the following issues:
MEDICARE/MEDICAID H.R.3: Lower Drug Costs Now Act of 2019. H.R.19: Lower Costs, More Cures Act of 2019. - Lobbyists: WILLCOX, DARREN
Foreign Entities: Foreign Entity Name: Suntory Holdings LimitedCountry : JAPANContribution : $0 |
Lobbying on the following issues:
BUDGET/APPROPRIATIONS HEALTH ISSUES H.R.1892: Bipartisan Budget Act of 2018 as it relates to a Part D donut hole provision. - H.R.5333: Over-the-Counter Monograph Safety, Innovation, and Reform Act of 2018. H.R.6378/S.2852: Reauthorization of PAHPA (Pandemic All-Hazards Preparedness Act). - Lobbyists: WILLCOX, DARREN
Foreign Entities: Foreign Entity Name: CACIFCountry : GUATEMALAContribution : $30,000 |
Lobbying on the following issues:
HEALTH ISSUES Education about the value of innovative medicines. - Lobbyists: WILLCOX, DARREN Held the following Government positions Asst. for Policy, Speaker Dennis Hastert Admin. Asst., Legislative Director, Legislative Asst., Cong. Porter Goss House Rules Comm. Assoc., Subcommittee Staff Director
Foreign Entities: Foreign Entity Name: CACIFCountry : GUATEMALAContribution : $30,000 |
Lobbying on the following issues:
HEALTH ISSUES Education about improvements to Prescription Drug Monitoring programs that would promote greater efficiency and utility at the pharmacy and other issues related to opioid abuse. - Lobbyists: WILLCOX, DARREN
Foreign Entities: Foreign Entity Name: CACIFCountry : GUATEMALAContribution : $30,000 |
Lobbying on the following issues:
HEALTH ISSUES TAXATION/INTERNAL REVENUE CODE H.R.7122: Shared Accountability for Improved Patient Outcomes Act of 2018, and other education related to value based healthcare arrangements. - H.R.4617: Protect Medical Innovation Act. H.R.88 as it relates to the medical device tax. - Lobbyists: WILLCOX, DARREN
Foreign Entities: Foreign Entity Name: CACIFCountry : GUATEMALAContribution : $30,000 |
Lobbying on the following issues:
HEALTH ISSUES MEDICARE/MEDICAID H.R.269: Pandemic and All-Hazards Preparedness and Advancing Innovation Act (PAHPA) reauthorization including the Over-the-Counter Monograph Safety, Innovation and Reform Act of 2018. - Regulatory and legislative proposals in the Administrations Blueprint. - Lobbyists: WILLCOX, DARREN
Foreign Entities: Foreign Entity Name: Samil Spinning Co., LtdCountry : NORTH KOREAContribution : $0 |
Lobbying on the following issues:
MEDICARE/MEDICAID HEALTH ISSUES Regulatory and legislative proposals in the Administrations Blueprint. - Education about the value of innovative medicines. - Lobbyists: WILLCOX, DARREN
Foreign Entities: Foreign Entity Name: Samil Spinning Co., LtdCountry : NORTH KOREAContribution : $0 |
Lobbying on the following issues:
MEDICARE/MEDICAID HEALTH ISSUES Regulatory and legislative proposals in the Administrations Blueprint. - Education about improvements to Prescription Drug Monitoring programs that would promote greater efficiency and utility at the pharmacy and other issues related to opioid abuse. - Lobbyists: WILLCOX, DARREN
Foreign Entities: Foreign Entity Name: Samil Spinning Co., LtdCountry : NORTH KOREAContribution : $0 |
Lobbying on the following issues:
TAXATION/INTERNAL REVENUE CODE HEALTH ISSUES H.R.2207: Protect Medical Innovation Act. - "Shared Accountability for Improved Patient Outcomes Act of 2018," and other education related to value based healthcare arrangements. - Lobbyists: WILLCOX, DARREN
Foreign Entities: Foreign Entity Name: Samil Spinning Co., LtdCountry : NORTH KOREAContribution : $0 |
Lobbying on the following issues:
MEDICARE/MEDICAID HEALTH ISSUES Regulatory and legislative proposals in the Administrations Blueprint. CMS rule dealing with removal of Safe Harbor Protection for Rebates Involving Prescription Pharmaceuticals. - H.R.269: Pandemic and All-Hazards Preparedness and Advancing Innovation Act (PAHPA) reauthorization including the Over-the-Counter Monograph Safety, Innovation and Reform Act of 2018. S.1260: Reducing Administrative Costs and Burdens in Health Care Act of 2019. Proposed legislation around cosmetics reform. - Lobbyists: WILLCOX, DARREN
|
Lobbying on the following issues:
HEALTH ISSUES MEDICARE/MEDICAID Education about the value of innovative medicines. - Regulatory and legislative proposals in the Administrations Blueprint. - Lobbyists: WILLCOX, DARREN
|
Lobbying on the following issues:
MEDICARE/MEDICAID HEALTH ISSUES TAXATION/INTERNAL REVENUE CODE Issues related to breakthrough medical technologies. Issues related to continuous glucose monitoring systems. - "Shared Accountability for Improved Patient Outcomes Act of 2018," and other education related to value based healthcare arrangements. - H.R.2207: Protect Medical Innovation Act. - Lobbyists: WILLCOX, DARREN
|
Lobbying on the following issues:
HEALTH ISSUES MEDICARE/MEDICAID TAXATION/INTERNAL REVENUE CODE H.R.3433: Over-the-Counter Monograph Safety, Innovation and Reform Act. Proposed legislation around FDA cosmetics reform. - Regulatory and legislative proposals in the Administrations Blueprint. H.R.3: Lower Drug Costs Now Act of 2019. S.2543: Prescription Drug Pricing Reduction Act of 2019. - S.1089: Restoring Access to Medication Act of 2019. - Lobbyists: WILLCOX, DARREN
Foreign Entities: Foreign Entity Name : Roivant Sciences Ltd.Country : BERMUDAContribution : $0 - Foreign Entity Name : Roivant Sciences Holdings Ltd.Country : UNITED KINGDOMContribution : $0 - |
Lobbying on the following issues:
MEDICARE/MEDICAID HEALTH ISSUES Regulatory and legislative proposals in the Administrations Blueprint. - Education about the value of innovative medicines. H.R.3: Lower Drug Costs Now Act of 2019. - Lobbyists: WILLCOX, DARREN
Foreign Entities: Foreign Entity Name : LVMH Moet Hennessy Louis Vuitton Inc.Country : FRANCEContribution : $0 - Foreign Entity Name : Sofidiv S.A.S.Country : FRANCEContribution : $0 - |
Lobbying on the following issues:
MEDICARE/MEDICAID CONSUMER ISSUES/SAFETY/PRODUCTS HEALTH ISSUES TAXATION/INTERNAL REVENUE CODE Issues related to breakthrough medical technologies. Issues related to continuous glucose monitoring systems. - Federal data privacy legislation. - "Shared Accountability for Improved Patient Outcomes Act of 2018," "PAVE Act", and other education related to value based healthcare arrangements. - H.R.2207: Protect Medical Innovation Act. - Lobbyists: WILLCOX, DARREN
Foreign Entities: Foreign Entity Name : LVMH Moet Hennessy Louis Vuitton Inc.Country : FRANCEContribution : $0 - Foreign Entity Name : Sofidiv S.A.S.Country : FRANCEContribution : $0 - |
Lobbying on the following issues:
MEDICARE/MEDICAID HEALTH ISSUES Regulatory and legislative proposals in the Administrations Blueprint. H.R.3: Lower Drug Costs Now Act of 2019. H.R.19: Lower Costs, More Cures Act of 2019. S.2543: Prescription Drug Pricing Reduction Act of 2019. - H.R.3433: Over-the-Counter Monograph Safety, Innovation and Reform Act. Proposed legislation around FDA cosmetics reform. - Lobbyists: WILLCOX, DARREN
Foreign Entities: Foreign Entity Name : Roivant Sciences Ltd.Country : BERMUDAContribution : $0 - Foreign Entity Name : Roivant Sciences GmbHCountry : SWITZERLANDContribution : $0 - Foreign Entity Name : Roivant Sciences Holdings Ltd.Country : UNITED KINGDOMContribution : $0 - |
Lobbying on the following issues:
MEDICARE/MEDICAID Regulatory and legislative proposals in the Administrations Blueprint. H.R.3: Lower Drug Costs Now Act of 2019. H.R.19: Lower Costs, More Cures Act of 2019. - Lobbyists: WILLCOX, DARREN
Foreign Entities: Foreign Entity Name : Roivant Sciences Ltd.Country : BERMUDAContribution : $0 - Foreign Entity Name : Roivant Sciences GmbHCountry : SWITZERLANDContribution : $0 - Foreign Entity Name : Roivant Sciences Holdings Ltd.Country : UNITED KINGDOMContribution : $0 - |
Lobbying on the following issues:
MEDICARE/MEDICAID CONSUMER ISSUES/SAFETY/PRODUCTS TAXATION/INTERNAL REVENUE CODE HEALTH ISSUES Issues related to breakthrough medical technologies. Issues related to continuous glucose monitoring systems. - Federal data privacy legislation. - H.R.1865, FY 2020 Appropriations as it relates to H.R.2207: Protect Medical Innovation Act. - "Shared Accountability for Improved Patient Outcomes Act of 2018," "PAVE Act", and other education related to value based healthcare arrangements. Administrations Proposed Rule on Safe Harbors/Anti-Kickback Statute. - Lobbyists: WILLCOX, DARREN
Foreign Entities: Foreign Entity Name : Roivant Sciences Ltd.Country : BERMUDAContribution : $0 - Foreign Entity Name : Roivant Sciences GmbHCountry : SWITZERLANDContribution : $0 - Foreign Entity Name : Roivant Sciences Holdings Ltd.Country : UNITED KINGDOMContribution : $0 - |
Lobbying on the following issues:
MEDICARE/MEDICAID HEALTH ISSUES Regulatory and legislative proposals in the Administrations Blueprint. H.R.3: Lower Drug Costs Now Act of 2019. H.R.19: Lower Costs, More Cures Act of 2019. S.2543: Prescription Drug Pricing Reduction Act of 2019. - H.R.748: Coronavirus Aid, Relief, and Economic Security Act or the CARES Act as it relates to H.R.3433: Over-the-Counter Monograph Safety, Innovation and Reform Act, and H.R.1922: Restoring Access to Medication Act of 2019. Proposed legislation around FDA cosmetics reform. Issues related to oral health. - Lobbyists: WILLCOX, DARREN
Foreign Entities: Foreign Entity Name: FCA Holdco BVCountry : UNITED KINGDOMContribution : $0 |
Lobbying on the following issues:
MEDICARE/MEDICAID Regulatory and legislative proposals in the Administrations Blueprint. H.R.3: Lower Drug Costs Now Act of 2019. H.R.19: Lower Costs, More Cures Act of 2019. - Lobbyists: WILLCOX, DARREN
Foreign Entities: Foreign Entity Name: FCA Holdco BVCountry : UNITED KINGDOMContribution : $0 |
Lobbying on the following issues:
MEDICARE/MEDICAID HEALTH ISSUES CONSUMER ISSUES/SAFETY/PRODUCTS H.R.5333: Ensuring Patient Access to Critical Breakthrough Products Act of 2019. - "Shared Accountability for Improved Patient Outcomes Act of 2018," "PAVE Act", and other education related to value based healthcare arrangements. Administrations Proposed Rule on Safe Harbors/Anti-Kickback Statute. Issues related to medical devices and COVID-19. - Federal data privacy legislation. - Lobbyists: WILLCOX, DARREN
Foreign Entities: Foreign Entity Name: FCA Holdco BVCountry : UNITED KINGDOMContribution : $0 |
Lobbying on the following issues:
TAXATION/INTERNAL REVENUE CODE HEALTH ISSUES H.R.184: Protect Medical Innovation Act and H.R.88 as it relates to the medical device tax. - Promoted life sciences community and communicated economic and health benefits of the industry. H.R.6378/S.2852: Reauthorization of PAHPA (Pandemic All-Hazards Preparedness Act). - Lobbyists: WILLCOX, DARREN
Foreign Entities: Foreign Entity Name: CACIFCountry : GUATEMALAContribution : $30,000 |
Lobbying on the following issues:
HEALTH ISSUES TAXATION/INTERNAL REVENUE CODE H.R.5333: Over-the-Counter Monograph Safety, Innovation, and Reform Act of 2018. - H.R.394: Restoring Access to Medication Act. - Lobbyists: WILLCOX, DARREN
Foreign Entities: Foreign Entity Name: CACIFCountry : GUATEMALAContribution : $30,000 |
Lobbying on the following issues:
MEDICARE/MEDICAID General Medicare issues affecting durable medical equipment (DME) reimbursement and regulation. Proposal by CMS to expand DME competitive bidding to include certain "off the shelf" knee and back braces. - Lobbyists: WILLCOX, DARREN
Foreign Entities: Foreign Entity Name: CACIFCountry : GUATEMALAContribution : $30,000 |
Lobbying on the following issues:
HEALTH ISSUES Implementation of the Affordable Care Act and regulation of short-term health insurance plans. - Lobbyists: WILLCOX, DARREN
Foreign Entities: Foreign Entity Name: CACIFCountry : GUATEMALAContribution : $30,000 |
Lobbying on the following issues:
MEDICARE/MEDICAID HEALTH ISSUES TAXATION/INTERNAL REVENUE CODE Education about CMS rule changing protections for beneficiaries in Medicare Part D six protected classes. Regulatory and legislative proposals in the Administrations Blueprint. - Promoted life sciences community and communicated economic and health benefits of the industry. S.344: Hatch-Waxman Integrity Act of 2019. H.R 269: Reauthorization of Pandemic and All-Hazards Preparedness and Advancing Innovation Act (PAHPA) of 2019. - H.R. 2207: Protect Medical Innovation Act. - Lobbyists: WILLCOX, DARREN
Foreign Entities: Foreign Entity Name: Samil Spinning Co., LtdCountry : NORTH KOREAContribution : $0 |
Lobbying on the following issues:
HEALTH ISSUES H.R.269: Pandemic and All-Hazards Preparedness and Advancing Innovation Act (PAHPA) reauthorization as it relates to the Over-the-Counter Monograph Safety, Innovation and Reform Act of 2018. - Lobbyists: WILLCOX, DARREN
Foreign Entities: Foreign Entity Name: Samil Spinning Co., LtdCountry : NORTH KOREAContribution : $0 |
Lobbying on the following issues:
MEDICARE/MEDICAID General Medicare issues affecting durable medical equipment (DME) reimbursement and regulation. Proposal by CMS to expand DME competitive bidding to include certain off the shelf knee and back braces. - Lobbyists: WILLCOX, DARREN
Foreign Entities: Foreign Entity Name: Samil Spinning Co., LtdCountry : NORTH KOREAContribution : $0 |
Lobbying on the following issues:
HEALTH ISSUES MEDICARE/MEDICAID Education about access to innovative therapies, especially in sickle cell disease. - Access to innovative therapies in the Medicaid program. - Lobbyists: WILLCOX, DARREN
Foreign Entities: Foreign Entity Name: Samil Spinning Co., LtdCountry : NORTH KOREAContribution : $0 |
Lobbying on the following issues:
HEALTH ISSUES Implementation of the Affordable Care Act and regulation of short-term health insurance plans. - Lobbyists: WILLCOX, DARREN
|
Lobbying on the following issues:
TAXATION/INTERNAL REVENUE CODE HEALTH ISSUES MEDICARE/MEDICAID H.R. 2207: Protect Medical Innovation Act. - Promoted life sciences community and communicated economic and health benefits of the industry. H.R 269: Reauthorization of Pandemic and All-Hazards Preparedness and Advancing Innovation Act (PAHPA) of 2019. - Regulatory and legislative proposals in the Administrations Blueprint. H.R.2113: Prescription Drug STAR Act. - Lobbyists: WILLCOX, DARREN
|
Lobbying on the following issues:
HEALTH ISSUES H.R.269: Pandemic and All-Hazards Preparedness and Advancing Innovation Act (PAHPA) reauthorization as it relates to the Over-the-Counter Monograph Safety, Innovation and Reform Act of 2018. S.: Lower Health Care Costs Act of 2019. - Lobbyists: WILLCOX, DARREN
|
Lobbying on the following issues:
MEDICARE/MEDICAID General Medicare issues affecting durable medical equipment (DME) reimbursement and regulation. Proposal by CMS to expand DME competitive bidding to include certain off the shelf knee and back braces. - Lobbyists: WILLCOX, DARREN
|
Lobbying on the following issues:
HEALTH ISSUES MEDICARE/MEDICAID Education about access to innovative therapies, especially in sickle cell disease. H.R.2113: Prescription Drug STAR Act. - Access to innovative therapies in the Medicaid program. - Lobbyists: WILLCOX, DARREN
|
Lobbying on the following issues:
HEALTH ISSUES Issues related to the Affordable Care Act and regulation of short-term health insurance plans. - Lobbyists: WILLCOX, DARREN
|
Lobbying on the following issues:
HEALTH ISSUES MEDICARE/MEDICAID TAXATION/INTERNAL REVENUE CODE Promoted life sciences community and communicated economic and health benefits of the industry. - Regulatory and legislative proposals in the Administrations Blueprint. H.R.2113: Prescription Drug STAR Act. H.R.2296: FAIR Drug Pricing Act. H.R.3: Lower Drug Costs Now Act of 2019. - H.R. 2207: Protect Medical Innovation Act. - Lobbyists: WILLCOX, DARREN
Foreign Entities: Foreign Entity Name : Roivant Sciences Ltd.Country : BERMUDAContribution : $0 - Foreign Entity Name : Roivant Sciences Holdings Ltd.Country : UNITED KINGDOMContribution : $0 - |
Lobbying on the following issues:
TAXATION/INTERNAL REVENUE CODE HEALTH ISSUES S.1089: Restoring Access to Medication Act of 2019. - H.R.3433: Over-the-Counter Monograph Safety, Innovation and Reform Act. Discussion draft on FDA cosmetics regulatory reform. - Lobbyists: WILLCOX, DARREN
Foreign Entities: Foreign Entity Name : Roivant Sciences Ltd.Country : BERMUDAContribution : $0 - Foreign Entity Name : Roivant Sciences Holdings Ltd.Country : UNITED KINGDOMContribution : $0 - |
Lobbying on the following issues:
MEDICARE/MEDICAID General Medicare issues affecting durable medical equipment (DME) reimbursement and regulation. - Lobbyists: WILLCOX, DARREN
Foreign Entities: Foreign Entity Name : Roivant Sciences Ltd.Country : BERMUDAContribution : $0 - Foreign Entity Name : Roivant Sciences Holdings Ltd.Country : UNITED KINGDOMContribution : $0 - |
Lobbying on the following issues:
HEALTH ISSUES MEDICARE/MEDICAID Education about access to innovative therapies, especially in sickle cell disease. H.R.2113: Prescription Drug STAR Act. - Access to innovative therapies in the Medicaid program. S.2543: Prescription Drug Pricing Reduction Act of 2019. - Lobbyists: WILLCOX, DARREN
Foreign Entities: Foreign Entity Name: Karsan AutomotiveCountry : TURKEYContribution : $0 |
Lobbying on the following issues:
HEALTH ISSUES H.R.269: Reauthorization of Pandemic and All-Hazards Preparedness and Advancing Innovation Act (PAHPA) of 2019. Education about MRNA technology. - Lobbyists: WILLCOX, DARREN
Foreign Entities: Foreign Entity Name : LVMH Moet Hennessy Louis Vuitton Inc.Country : FRANCEContribution : $0 - Foreign Entity Name : Sofidiv S.A.S.Country : FRANCEContribution : $0 - |
Lobbying on the following issues:
HEALTH ISSUES Regulation of short-term health insurance plans. - Lobbyists: WILLCOX, DARREN
Foreign Entities: Foreign Entity Name : LVMH Moet Hennessy Louis Vuitton Inc.Country : FRANCEContribution : $0 - Foreign Entity Name : Sofidiv S.A.S.Country : FRANCEContribution : $0 - |
Lobbying on the following issues:
MEDICARE/MEDICAID HEALTH ISSUES TAXATION/INTERNAL REVENUE CODE Regulatory and legislative proposals in the Administrations Blueprint. H.R.3: Lower Drug Costs Now Act of 2019. H.R.19: Lower Costs, More Cures Act of 2019. - Promoted life sciences community and communicated economic and health benefits of the industry. - H.R.1865: FY 2020 Appropriations as it relates to H.R.2207: Protect Medical Innovation Act. - Lobbyists: WILLCOX, DARREN
Foreign Entities: Foreign Entity Name : Roivant Sciences Ltd.Country : BERMUDAContribution : $0 - Foreign Entity Name : Roivant Sciences GmbHCountry : SWITZERLANDContribution : $0 - Foreign Entity Name : Roivant Sciences Holdings Ltd.Country : UNITED KINGDOMContribution : $0 - |
Lobbying on the following issues:
HEALTH ISSUES TAXATION/INTERNAL REVENUE CODE H.R.3433: Over-the-Counter Monograph Safety, Innovation and Reform Act. Discussion draft on FDA cosmetics regulatory reform. - S.1089: Restoring Access to Medication Act of 2019. - Lobbyists: WILLCOX, DARREN
Foreign Entities: Foreign Entity Name : Roivant Sciences Ltd.Country : BERMUDAContribution : $0 - Foreign Entity Name : Roivant Sciences GmbHCountry : SWITZERLANDContribution : $0 - Foreign Entity Name : Roivant Sciences Holdings Ltd.Country : UNITED KINGDOMContribution : $0 - |
Lobbying on the following issues:
MEDICARE/MEDICAID General Medicare issues affecting durable medical equipment (DME) reimbursement and regulation. - Lobbyists: WILLCOX, DARREN
Foreign Entities: Foreign Entity Name : Roivant Sciences Ltd.Country : BERMUDAContribution : $0 - Foreign Entity Name : Roivant Sciences GmbHCountry : SWITZERLANDContribution : $0 - Foreign Entity Name : Roivant Sciences Holdings Ltd.Country : UNITED KINGDOMContribution : $0 - |
Lobbying on the following issues:
MEDICARE/MEDICAID HEALTH ISSUES Access to innovative therapies in the Medicaid program. S.2543: Prescription Drug Pricing Reduction Act of 2019. H.R.3: Lower Drug Costs Now Act of 2019. H.R.19: Lower Costs, More Cures Act of 2019. - Education about access to innovative therapies, especially in sickle cell disease. H.R.2113: Prescription Drug STAR Act. - Lobbyists: WILLCOX, DARREN
Foreign Entities: Foreign Entity Name : Roivant Sciences Ltd.Country : BERMUDAContribution : $0 - Foreign Entity Name : Roivant Sciences GmbHCountry : SWITZERLANDContribution : $0 - Foreign Entity Name : Roivant Sciences Holdings Ltd.Country : UNITED KINGDOMContribution : $0 - |
Lobbying on the following issues:
HEALTH ISSUES Regulation of short-term health insurance plans. Administration Executive Order on health care transparency. - Lobbyists: WILLCOX, DARREN
Foreign Entities: Foreign Entity Name : Roivant Sciences Ltd.Country : BERMUDAContribution : $0 - Foreign Entity Name : Roivant Sciences GmbHCountry : SWITZERLANDContribution : $0 - Foreign Entity Name : Roivant Sciences Holdings Ltd.Country : UNITED KINGDOMContribution : $0 - |
Lobbying on the following issues:
MEDICARE/MEDICAID H.R.3: Lower Drug Costs Now Act of 2019. H.R.19: Lower Costs, More Cures Act of 2019. - Lobbyists: WILLCOX, DARREN
Foreign Entities: Foreign Entity Name: CRISPR Therapeutics AGCountry : SWITZERLANDContribution : $100,000 |
Lobbying on the following issues:
HEALTH ISSUES BUDGET/APPROPRIATIONS MEDICARE/MEDICAID Promoted life sciences community and communicated economic and health benefits of the industry. - H.R.6074: Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020. - Regulatory and legislative proposals in the Administrations Blueprint. H.R.3: Lower Drug Costs Now Act of 2019. H.R.19: Lower Costs, More Cures Act of 2019. - Lobbyists: WILLCOX, DARREN
|
Lobbying on the following issues:
HEALTH ISSUES MEDICARE/MEDICAID Education around regulation of bone growth stimulation devices and potential FDA reclassification of BGS devices. - General Medicare issues affecting durable medical equipment (DME) reimbursement and regulation. - Lobbyists: WILLCOX, DARREN
|
Lobbying on the following issues:
MEDICARE/MEDICAID HEALTH ISSUES S.2543: Prescription Drug Pricing Reduction Act of 2019. H.R.3: Lower Drug Costs Now Act of 2019. H.R.19: Lower Costs, More Cures Act of 2019. - Education about access to innovative therapies, especially in sickle cell disease. - Lobbyists: WILLCOX, DARREN
Foreign Entities: Foreign Entity Name: FCA Holdco BVCountry : UNITED KINGDOMContribution : $0 |
Lobbying on the following issues:
MEDICARE/MEDICAID H.R.3: Lower Drug Costs Now Act of 2019. H.R.19: Lower Costs, More Cures Act of 2019. - Lobbyists: WILLCOX, DARREN
Foreign Entities: Foreign Entity Name: FCA Holdco BVCountry : UNITED KINGDOMContribution : $0 |
Lobbying on the following issues:
HEALTH ISSUES Regulation of short-term health insurance plans. Administration Executive Order on health care transparency. S.3548: Coronavirus Aid, Relief, and Economic Security Act or the CARES Act. - Lobbyists: WILLCOX, DARREN
Foreign Entities: Foreign Entity Name : Canadian NationalCountry : CANADAContribution : $122,024 - Foreign Entity Name : Canadian PacificCountry : CANADAContribution : $0 - |
Lobbying on the following issues:
MEDICAL/DISEASE RESEARCH/CLINICAL LABS Issues related to regulation of Direct to Consumer (DTC) Genetic Testing and education and outreach regarding genetic testing and personalized medicine, including FDA regulation of DTC tests and privacy in consumer genetics. - Lobbyists: WILLCOX, DARREN
Foreign Entities: Foreign Entity Name: CACIFCountry : GUATEMALAContribution : $30,000 |
Lobbying on the following issues:
MEDICAL/DISEASE RESEARCH/CLINICAL LABS Issues related to regulation of Direct to Consumer (DTC) Genetic Testing and education and outreach regarding genetic testing and personalized medicine, including FDA regulation of DTC tests and privacy in consumer genetics. - Lobbyists: WILLCOX, DARREN
Foreign Entities: Foreign Entity Name: Samil Spinning Co., LtdCountry : NORTH KOREAContribution : $0 |
Lobbying on the following issues:
MEDICAL/DISEASE RESEARCH/CLINICAL LABS Issues related to regulation of Direct to Consumer (DTC) Genetic Testing and education and outreach regarding genetic testing and personalized medicine, including FDA regulation of DTC tests and privacy in consumer genetics. - Lobbyists: WILLCOX, DARREN
|
Lobbying on the following issues:
MEDICAL/DISEASE RESEARCH/CLINICAL LABS Issues related to regulation of Direct to Consumer (DTC) Genetic Testing and education and outreach regarding genetic testing and personalized medicine, including FDA regulation of DTC tests and privacy in consumer genetics. - Lobbyists: WILLCOX, DARREN
Foreign Entities: Foreign Entity Name : Roivant Sciences Ltd.Country : BERMUDAContribution : $0 - Foreign Entity Name : Roivant Sciences Holdings Ltd.Country : UNITED KINGDOMContribution : $0 - |
Lobbying on the following issues:
HEALTH ISSUES Education around access to innovative cancer therapies. - Lobbyists: WILLCOX, DARREN
Foreign Entities: Foreign Entity Name : LVMH Moet Hennessy Louis Vuitton Inc.Country : FRANCEContribution : $0 - Foreign Entity Name : Sofidiv S.A.S.Country : FRANCEContribution : $0 - |
Lobbying on the following issues:
MEDICAL/DISEASE RESEARCH/CLINICAL LABS Issues related to regulation of Direct to Consumer (DTC) Genetic Testing and education and H. outreach regarding genetic testing and personalized medicine, including FDA regulation of DTC tests and privacy in consumer genetics. - Lobbyists: WILLCOX, DARREN
Foreign Entities: Foreign Entity Name : Roivant Sciences Ltd.Country : BERMUDAContribution : $0 - Foreign Entity Name : Roivant Sciences GmbHCountry : SWITZERLANDContribution : $0 - Foreign Entity Name : Roivant Sciences Holdings Ltd.Country : UNITED KINGDOMContribution : $0 - |
Lobbying on the following issues:
MEDICAL/DISEASE RESEARCH/CLINICAL LABS Issues related to regulation of Direct to Consumer (DTC) Genetic Testing and education and outreach regarding genetic testing and personalized medicine, including FDA regulation of DTC tests and privacy in consumer genetics. - Lobbyists: WILLCOX, DARREN
Foreign Entities: Foreign Entity Name: Horizon Pharma PLCCountry : IRELANDContribution : $0 |
Lobbying on the following issues:
HEALTH ISSUES H.R.269: Reauthorization of Pandemic and All-Hazards Preparedness and Advancing Innovation Act (PAHPA) of 2019. Education about MRNA technology. - Lobbyists: WILLCOX, DARREN
|
Lobbying on the following issues:
HEALTH ISSUES Education around potential COVID-19 vaccines and related issues. H.R.748: Coronavirus Aid, Relief, and Economic Security Act or the CARES Act. - Lobbyists: WILLCOX, DARREN
Foreign Entities: Foreign Entity Name : Canadian NationalCountry : CANADAContribution : $122,024 - Foreign Entity Name : Canadian PacificCountry : CANADAContribution : $0 - |
Lobbying on the following issues:
HEALTH ISSUES Education about access to innovative therapies, especially in sickle cell disease. - Lobbyists: WILLCOX, DARREN Held the following Government positions Asst. for Policy, Speaker Dennis Hastert Admin. Asst., Legislative Director, Legislative Asst., Cong. Porter Goss House Rules Comm. Assoc., Subcommittee Staff Director
Foreign Entities: Foreign Entity Name: Luen Thai Footwear MacauCountry : CHINAContribution : $20,000 |
Lobbying on the following issues:
HEALTH ISSUES Education around access to innovative cancer therapies. - Lobbyists: WILLCOX, DARREN Held the following Government positions Asst. for Policy, Speaker Dennis Hastert Admin. Asst., Legislative Director, Legislative Asst., Cong. Porter Goss House Rules Comm. Assoc., Subcommittee Staff Director
Foreign Entities: Foreign Entity Name: GlaxoSmithKline plcCountry : UNITED KINGDOMContribution : $0 |
Lobbying on the following issues:
MEDICARE/MEDICAID 6 protected classes. Medicare Part D. - Lobbyists: WILLCOX, DARREN Held the following Government positions Asst. for Policy, Speaker Dennis Hastert Admin. Asst., Legislative Director, Legislative Asst., Cong. Porter Goss House Rules Comm. Assoc., Subcommittee Staff Director
Foreign Entities: Foreign Entity Name : Institute of Water Policy, Lee Kuan Yew School of Public Policy, National University of SingaporeCountry : SINGAPOREContribution : $14 - Foreign Entity Name : Asociacion Espanola de Reutilizacion Sostenible del Agua (ASERSA)Country : SPAINContribution : $0 - Foreign Entity Name : Greyter Water SystemsCountry : CANADAContribution : $0 - Foreign Entity Name : Purifics Water Inc.Country : CANADAContribution : $0 - Foreign Entity Name : WPC Solutions Inc.Country : CANADAContribution : $0 - Foreign Entity Name : University of MelbourneCountry : AUSTRALIAContribution : $0 - Foreign Entity Name : Aquacion Group inc.Country : CANADAContribution : $0 - Foreign Entity Name : Alberta Agriculture & ForestryCountry : CANADAContribution : $0 - Foreign Entity Name : University of Toronto - Drinking Water Research GroupCountry : CANADAContribution : $0 - Foreign Entity Name : Cranfield Water Science InstituteCountry : UNITED KINGDOMContribution : $0 - Foreign Entity Name : Nagasaki UniversityCountry : JAPANContribution : $0 - Foreign Entity Name : City West WaterCountry : AUSTRALIAContribution : $0 - Foreign Entity Name : Tsinghua UniversityCountry : CHINAContribution : $0 - Foreign Entity Name : TrojanUVCountry : CANADAContribution : $0 - Foreign Entity Name : Ministry of the Environment, Conservation and ParksCountry : CANADAContribution : $0 - Foreign Entity Name : Sustainable Water SolutionsCountry : AUSTRALIAContribution : $0 - Foreign Entity Name : Proteus WatersCountry : CANADAContribution : $0 - Foreign Entity Name : Hotaru Co.Country : JAPANContribution : $0 - Foreign Entity Name : IDE Technologies, Ltd.Country : ISRAELContribution : $0 - |
Lobbying on the following issues:
MEDICARE/MEDICAID Regulatory and legislative proposals in the Administrations Blueprint. - Lobbyists: WILLCOX, DARREN
|
Lobbying on the following issues:
HEALTH ISSUES Education around mRNA technology. - Lobbyists: WILLCOX, DARREN Held the following Government positions ​Asst. for Policy, Speaker Dennis Hastert Admin. Asst., Legislative Director, Legislative Asst., Cong. Porter Goss House Rules Comm. Assoc., Subcommittee Staff Director
Foreign Entities: Foreign Entity Name: SoftBank Group CorpCountry : JAPANContribution : $240,000 |
Lobbying on the following issues:
MEDICARE/MEDICAID Issues around Medicare Part D. - Lobbyists: WILLCOX, DARREN Held the following Government positions ​​Asst. for Policy, Speaker Dennis Hastert Admin. Asst., Legislative Director, Legislative Asst., Cong. Porter Goss House Rules Comm. Assoc., Subcommittee Staff Director
Foreign Entities: Foreign Entity Name: Svante, Inc.Country : CANADAContribution : $45,000 |
Lobbying on the following issues:
COMMUNICATIONS/BROADCASTING/RADIO/TV Broadband Infrastructure Issues Broadband Adoption - Lobbyists: GRIFFIN, BRIANSCHIAPPA, DAVID J
Foreign Entities: Foreign Entity Name : Roivant Sciences Ltd.Country : BERMUDAContribution : $0 - Foreign Entity Name : Roivant Sciences GmbHCountry : SWITZERLANDContribution : $0 - Foreign Entity Name : Roivant Sciences Holdings Ltd.Country : UNITED KINGDOMContribution : $0 - |
Lobbying on the following issues:
HEALTH ISSUES Education around potential COVID-19 vaccines and related issues. - Lobbyists: WILLCOX, DARREN Held the following Government positions ​​Asst. for Policy, Speaker Dennis Hastert Admin. Asst., Legislative Director, Legislative Asst., Cong. Porter Goss House Rules Comm. Assoc., Subcommittee Staff Director
Foreign Entities: Foreign Entity Name: Mitsubishi Heavy IndustriesCountry : JAPANContribution : $0 |
Lobbying on the following issues:
HOMELAND SECURITY Education around Secure Identity's health pass technology and related issues. - Lobbyists: WILLCOX, DARREN Held the following Government positions ​​​Asst. for Policy, Speaker Dennis Hastert Admin. Asst., Legislative Director, Legislative Asst., Cong. Porter Goss House Rules Comm. Assoc., Subcommittee Staff Director
Foreign Entities: Foreign Entity Name: ABC-Mart, Inc.Country : JAPANContribution : $0 |
Money Spent:
Amount | Client | Government Entities |
---|
$60,000
Jan 22, 2019
FOURTH QUARTER REPORT
Alexion Pharmaceuticals
Biopharmaceutical leader in the development of treatments for rare diseases
SENATEHOUSE OF REPRESENTATIVES
$60,000
Jan 22, 2019
FOURTH QUARTER REPORT
JUUL LABS INC
Vaporizers and e-cigarettes manufacturer and supplier.
SENATEHOUSE OF REPRESENTATIVES
$60,000
Jan 22, 2019
FOURTH QUARTER REPORT
Pharmaceutical Research and Manufacturers of America
A trade group representing pharmaceutical research and biotechnology companies.
SENATEHOUSE OF REPRESENTATIVES
$60,000
Apr 22, 2019
FIRST QUARTER REPORT
Alexion Pharmaceuticals
Biopharmaceutical leader in the development of treatments for rare diseases
SENATEHOUSE OF REPRESENTATIVES
$60,000
Apr 22, 2019
FIRST QUARTER REPORT
Gilead Sciences, Inc.
American biotechnology company that researches, develops and commercializes drugs.
SENATEHOUSE OF REPRESENTATIVES
$60,000
Apr 22, 2019
FIRST QUARTER REPORT
JUUL LABS INC
Vaporizers and e-cigarettes manufacturer and supplier.
SENATEHOUSE OF REPRESENTATIVES
$60,000
Apr 22, 2019
FIRST QUARTER REPORT
Pharmaceutical Research and Manufacturers of America
A trade group representing pharmaceutical research and biotechnology companies.
SENATEHOUSE OF REPRESENTATIVES
$60,000
Jul 22, 2019
SECOND QUARTER REPORT
Alexion Pharmaceuticals
Biopharmaceutical leader in the development of treatments for rare diseases
SENATEHOUSE OF REPRESENTATIVES
$60,000
Jul 22, 2019
SECOND QUARTER REPORT
Gilead Sciences, Inc.
American biotechnology company that researches, develops and commercializes drugs.
SENATEHOUSE OF REPRESENTATIVES
$60,000
Jul 22, 2019
SECOND QUARTER REPORT
JUUL LABS INC
Vaporizers and e-cigarettes manufacturer and supplier.
SENATEHOUSE OF REPRESENTATIVES
$60,000
Jul 22, 2019
SECOND QUARTER REPORT
Pharmaceutical Research and Manufacturers of America
A trade group representing pharmaceutical research and biotechnology companies.
SENATEHOUSE OF REPRESENTATIVES
$60,000
Oct 21, 2019
THIRD QUARTER REPORT
Alexion Pharmaceuticals
Biopharmaceutical leader in the development of treatments for rare diseases
SENATEHOUSE OF REPRESENTATIVES
$60,000
Oct 21, 2019
THIRD QUARTER REPORT
Gilead Sciences, Inc.
American biotechnology company that researches, develops and commercializes drugs.
SENATEHOUSE OF REPRESENTATIVES
$60,000
Oct 21, 2019
THIRD QUARTER REPORT
JUUL LABS INC
Vaporizers and e-cigarettes manufacturer and supplier.
SENATEHOUSE OF REPRESENTATIVES
$60,000
Oct 21, 2019
THIRD QUARTER REPORT
Pharmaceutical Research and Manufacturers of America
A trade group representing pharmaceutical research and biotechnology companies.
SENATEHOUSE OF REPRESENTATIVES
$60,000
Jan 21, 2020
FOURTH QUARTER REPORT
Alexion Pharmaceuticals
Biopharmaceutical leader in the development of treatments for rare diseases
SENATEHOUSE OF REPRESENTATIVES
$60,000
Jan 21, 2020
FOURTH QUARTER REPORT
Gilead Sciences, Inc.
American biotechnology company that researches, develops and commercializes drugs.
SENATEHOUSE OF REPRESENTATIVES
$60,000
Jan 21, 2020
FOURTH QUARTER REPORT
JUUL LABS INC
Vaporizers and e-cigarettes manufacturer and supplier.
SENATEHOUSE OF REPRESENTATIVES
$60,000
Jan 21, 2020
FOURTH QUARTER REPORT
Pharmaceutical Research and Manufacturers of America
A trade group representing pharmaceutical research and biotechnology companies.
SENATEHOUSE OF REPRESENTATIVES
$60,000
Apr 20, 2020
FIRST QUARTER REPORT
Alexion Pharmaceuticals
Biopharmaceutical leader in the development of treatments for rare diseases
SENATEHOUSE OF REPRESENTATIVES
$60,000
Apr 20, 2020
FIRST QUARTER REPORT
AstraZeneca Pharmaceuticals LP
Biopharmaceutical Company.
SENATEHOUSE OF REPRESENTATIVES
$60,000
Apr 20, 2020
FIRST QUARTER REPORT
Gilead Sciences, Inc.
American biotechnology company that researches, develops and commercializes drugs.
SENATEHOUSE OF REPRESENTATIVES
$60,000
Apr 20, 2020
FIRST QUARTER REPORT
Pharmaceutical Research and Manufacturers of America
A trade group representing pharmaceutical research and biotechnology companies.
SENATEHOUSE OF REPRESENTATIVES
$60,000
Apr 20, 2020
FIRST QUARTER REPORT
JUUL LABS INC
Vaporizers and e-cigarettes manufacturer and supplier.
SENATEHOUSE OF REPRESENTATIVES
$50,000
Jan 22, 2019
FOURTH QUARTER REPORT
Abbott Laboratories
A pharmaceuticals health care company.
SENATEHOUSE OF REPRESENTATIVES
$50,000
Jan 22, 2019
FOURTH QUARTER REPORT
AbbVie Inc.
Biopharmaceutical company.
SENATEHOUSE OF REPRESENTATIVES
$50,000
Jan 22, 2019
FOURTH QUARTER REPORT
AstraZeneca Pharmaceuticals LP
Biopharmaceutical Company.
SENATEHOUSE OF REPRESENTATIVES
$50,000
Jan 22, 2019
FOURTH QUARTER TERMINATION
BIOGEN
Medical Technology Firm
SENATEHOUSE OF REPRESENTATIVES
$50,000
Jan 22, 2019
FOURTH QUARTER REPORT
Merck & Co., Inc.
Pharmaceutical Company.
SENATEHOUSE OF REPRESENTATIVES
$50,000
Jan 22, 2019
FOURTH QUARTER REPORT
SAGE Therapeutics
A clinical-stage biopharmaceutical company.
SENATEHOUSE OF REPRESENTATIVES
$50,000
Jan 22, 2019
FOURTH QUARTER REPORT
Sanofi U.S. Services, Inc.
Global life sciences company.
SENATEHOUSE OF REPRESENTATIVES
$50,000
Apr 22, 2019
FIRST QUARTER REPORT
Abbott Laboratories
A pharmaceuticals health care company.
SENATEHOUSE OF REPRESENTATIVES
$50,000
Apr 22, 2019
FIRST QUARTER REPORT
AbbVie Inc.
Biopharmaceutical company.
SENATEHOUSE OF REPRESENTATIVES
$50,000
Apr 22, 2019
FIRST QUARTER REPORT
AstraZeneca Pharmaceuticals LP
Biopharmaceutical Company.
SENATEHOUSE OF REPRESENTATIVES
$50,000
Apr 22, 2019
FIRST QUARTER REPORT
SAGE Therapeutics
A clinical-stage biopharmaceutical company.
SENATEHOUSE OF REPRESENTATIVES
$50,000
Apr 22, 2019
FIRST QUARTER REPORT
Sanofi U.S. Services, Inc.
Global life sciences company.
SENATEHOUSE OF REPRESENTATIVES
$50,000
Apr 22, 2019
FIRST QUARTER REPORT
TESARO, Inc.
Biopharmaceutical company.
SENATEHOUSE OF REPRESENTATIVES
$50,000
Apr 22, 2019
FIRST QUARTER REPORT
Merck & Co., Inc.
Pharmaceutical Company.
SENATEHOUSE OF REPRESENTATIVES
$50,000
Jul 22, 2019
SECOND QUARTER REPORT
Abbott Laboratories
A pharmaceuticals health care company.
SENATEHOUSE OF REPRESENTATIVES
$50,000
Jul 22, 2019
SECOND QUARTER REPORT
AbbVie Inc.
Biopharmaceutical company.
SENATEHOUSE OF REPRESENTATIVES
$50,000
Jul 22, 2019
SECOND QUARTER REPORT
AstraZeneca Pharmaceuticals LP
Biopharmaceutical Company.
SENATEHOUSE OF REPRESENTATIVES
$50,000
Jul 22, 2019
SECOND QUARTER REPORT
Merck & Co., Inc.
Pharmaceutical Company.
SENATEHOUSE OF REPRESENTATIVES
$50,000
Jul 22, 2019
SECOND QUARTER REPORT
SAGE Therapeutics
A clinical-stage biopharmaceutical company.
SENATEHOUSE OF REPRESENTATIVES
$50,000
Jul 22, 2019
SECOND QUARTER REPORT
Sanofi U.S. Services, Inc.
Global life sciences company.
SENATEHOUSE OF REPRESENTATIVES
$50,000
Jul 22, 2019
SECOND QUARTER REPORT
TESARO, Inc.
Biopharmaceutical company.
SENATEHOUSE OF REPRESENTATIVES
$50,000
Oct 21, 2019
THIRD QUARTER REPORT
Abbott Laboratories
A pharmaceuticals health care company.
SENATEHOUSE OF REPRESENTATIVES
$50,000
Oct 21, 2019
THIRD QUARTER REPORT
AbbVie Inc.
Biopharmaceutical company.
SENATEHOUSE OF REPRESENTATIVES
$50,000
Oct 21, 2019
THIRD QUARTER REPORT
AstraZeneca Pharmaceuticals LP
Biopharmaceutical Company.
SENATEHOUSE OF REPRESENTATIVES
$50,000
Oct 21, 2019
THIRD QUARTER REPORT
Merck & Co., Inc.
Pharmaceutical Company.
SENATEHOUSE OF REPRESENTATIVES
$50,000
Oct 21, 2019
THIRD QUARTER REPORT
SAGE Therapeutics
A clinical-stage biopharmaceutical company.
SENATEHOUSE OF REPRESENTATIVES
$50,000
Oct 21, 2019
THIRD QUARTER REPORT
Sanofi U.S. Services, Inc.
Global life sciences company.
SENATEHOUSE OF REPRESENTATIVES
$50,000
Jan 21, 2020
FOURTH QUARTER REPORT
Abbott Laboratories
A pharmaceuticals health care company.
SENATEHOUSE OF REPRESENTATIVES
$50,000
Jan 21, 2020
FOURTH QUARTER REPORT
AbbVie Inc.
Biopharmaceutical company.
SENATEHOUSE OF REPRESENTATIVES
$50,000
Jan 21, 2020
FOURTH QUARTER REPORT
AstraZeneca Pharmaceuticals LP
Biopharmaceutical Company.
SENATEHOUSE OF REPRESENTATIVES
$50,000
Jan 21, 2020
FOURTH QUARTER REPORT
Merck & Co., Inc.
Pharmaceutical Company.
SENATEHOUSE OF REPRESENTATIVES
$50,000
Jan 21, 2020
FOURTH QUARTER REPORT
SAGE Therapeutics
A clinical-stage biopharmaceutical company.
SENATEHOUSE OF REPRESENTATIVES
$50,000
Jan 21, 2020
FOURTH QUARTER REPORT
Sanofi U.S. Services, Inc.
Global life sciences company.
SENATEHOUSE OF REPRESENTATIVES
$50,000
Apr 20, 2020
FIRST QUARTER REPORT
Abbott Laboratories
A pharmaceuticals health care company.
SENATEHOUSE OF REPRESENTATIVES
$50,000
Apr 20, 2020
FIRST QUARTER REPORT
AbbVie Inc.
Biopharmaceutical company.
SENATEHOUSE OF REPRESENTATIVES
$50,000
Apr 20, 2020
FIRST QUARTER REPORT
Merck & Co., Inc.
Pharmaceutical Company.
SENATEHOUSE OF REPRESENTATIVES
$50,000
Apr 20, 2020
FIRST QUARTER REPORT
SAGE Therapeutics
A clinical-stage biopharmaceutical company.
SENATEHOUSE OF REPRESENTATIVES
$50,000
Apr 20, 2020
FIRST QUARTER REPORT
Sanofi U.S. Services, Inc.
Global life sciences company.
SENATEHOUSE OF REPRESENTATIVES
$50,000
Apr 27, 2020
FIRST QUARTER AMENDMENT
INCYTE CORPORATION
​Biopharmaceutical Company.
SENATEHOUSE OF REPRESENTATIVES
$40,000
Jan 22, 2019
FOURTH QUARTER REPORT
GLAXOSMITHKLINE
Healthcare company.
SENATEHOUSE OF REPRESENTATIVES
$40,000
Jan 22, 2019
FOURTH QUARTER REPORT
Ipsen Biopharmaceuticals, Inc.
Biopharmaceutical company.
SENATEHOUSE OF REPRESENTATIVES
$40,000
Jan 22, 2019
FOURTH QUARTER REPORT
McKesson Corporation
Health care services company
SENATEHOUSE OF REPRESENTATIVES
$40,000
Jan 22, 2019
FOURTH QUARTER REPORT
Medtronic, Inc.
Leader in medical technology providing lifelong solutions for people with chronic pain.
SENATEHOUSE OF REPRESENTATIVES
$40,000
Apr 22, 2019
FIRST QUARTER REPORT
GLAXOSMITHKLINE
Healthcare company.
SENATEHOUSE OF REPRESENTATIVES
$40,000
Apr 22, 2019
FIRST QUARTER REPORT
Ipsen Biopharmaceuticals, Inc.
Biopharmaceutical company.
SENATEHOUSE OF REPRESENTATIVES
$40,000
Apr 22, 2019
FIRST QUARTER REPORT
McKesson Corporation
Health care services company
SENATEHOUSE OF REPRESENTATIVES
$40,000
Apr 22, 2019
FIRST QUARTER REPORT
Medtronic, Inc.
Leader in medical technology providing lifelong solutions for people with chronic pain.
SENATEHOUSE OF REPRESENTATIVES
$40,000
Jul 22, 2019
SECOND QUARTER REPORT
GLAXOSMITHKLINE
Healthcare company.
SENATEHOUSE OF REPRESENTATIVES
$40,000
Jul 22, 2019
SECOND QUARTER REPORT
Ipsen Biopharmaceuticals, Inc.
Biopharmaceutical company.
SENATEHOUSE OF REPRESENTATIVES
$40,000
Jul 22, 2019
SECOND QUARTER REPORT
Medtronic, Inc.
Leader in medical technology providing lifelong solutions for people with chronic pain.
SENATEHOUSE OF REPRESENTATIVES
$40,000
Oct 21, 2019
THIRD QUARTER REPORT
GLAXOSMITHKLINE
Healthcare company.
SENATEHOUSE OF REPRESENTATIVES
$40,000
Oct 21, 2019
THIRD QUARTER REPORT
Ipsen Biopharmaceuticals, Inc.
Biopharmaceutical company.
SENATEHOUSE OF REPRESENTATIVES
$40,000
Oct 21, 2019
THIRD QUARTER REPORT
Medtronic, Inc.
Leader in medical technology providing lifelong solutions for people with chronic pain.
SENATEHOUSE OF REPRESENTATIVES
$40,000
Jan 21, 2020
FOURTH QUARTER REPORT
GLAXOSMITHKLINE
Healthcare company.
SENATEHOUSE OF REPRESENTATIVES
$40,000
Jan 21, 2020
FOURTH QUARTER REPORT
Ipsen Biopharmaceuticals, Inc.
Biopharmaceutical company.
SENATEHOUSE OF REPRESENTATIVES
$40,000
Jan 21, 2020
FOURTH QUARTER REPORT
Medtronic, Inc.
Leader in medical technology providing lifelong solutions for people with chronic pain.
SENATEHOUSE OF REPRESENTATIVES
$40,000
Apr 20, 2020
FIRST QUARTER REPORT
GLAXOSMITHKLINE
Healthcare company.
SENATEHOUSE OF REPRESENTATIVES
$40,000
Apr 20, 2020
FIRST QUARTER REPORT
Ipsen Biopharmaceuticals, Inc.
Biopharmaceutical company.
SENATEHOUSE OF REPRESENTATIVES
$40,000
Apr 20, 2020
FIRST QUARTER REPORT
Medtronic, Inc.
Leader in medical technology providing lifelong solutions for people with chronic pain.
SENATEHOUSE OF REPRESENTATIVES
$30,000
Jan 22, 2019
FOURTH QUARTER REPORT
CALIFORNIA LIFE SCIENCES ASSOCIATION
A public policy research and advocacy organization for California's biomedical industry.
SENATEHOUSE OF REPRESENTATIVES
$30,000
Jan 22, 2019
FOURTH QUARTER REPORT
Consumer Healthcare Products Association
Non-profit representing the makers of over-the-counter medicines & nutritional supplements
SENATEHOUSE OF REPRESENTATIVES
$30,000
Jan 22, 2019
FOURTH QUARTER REPORT
DJO Incorporated
Provider of high-quality, orthopedic devices.
SENATEHOUSE OF REPRESENTATIVES
$30,000
Jan 22, 2019
FOURTH QUARTER REPORT
UNITED SERVICES AUTOMOBILE ASSOCIATION (USAA)
Insurance and Financial Institution
SENATEHOUSE OF REPRESENTATIVES
$30,000
Apr 22, 2019
FIRST QUARTER REPORT
CALIFORNIA LIFE SCIENCES ASSOCIATION
A public policy research and advocacy organization for California's biomedical industry.
SENATEHOUSE OF REPRESENTATIVES
$30,000
Apr 22, 2019
FIRST QUARTER REPORT
Consumer Healthcare Products Association
Non-profit representing the makers of over-the-counter medicines & nutritional supplements
SENATEHOUSE OF REPRESENTATIVES
$30,000
Apr 22, 2019
FIRST QUARTER REPORT
DJO Incorporated
Provider of high-quality, orthopedic devices.
SENATEHOUSE OF REPRESENTATIVES
$30,000
Apr 22, 2019
FIRST QUARTER REPORT
Global Blood Therapeutics
Biopharmaceutical Research Company.
SENATEHOUSE OF REPRESENTATIVES
$30,000
Apr 22, 2019
FIRST QUARTER REPORT
UNITED SERVICES AUTOMOBILE ASSOCIATION (USAA)
Insurance and Financial Institution
SENATEHOUSE OF REPRESENTATIVES
$30,000
Jul 22, 2019
SECOND QUARTER REPORT
CALIFORNIA LIFE SCIENCES ASSOCIATION
A public policy research and advocacy organization for California's biomedical industry.
SENATEHOUSE OF REPRESENTATIVES
$30,000
Jul 22, 2019
SECOND QUARTER REPORT
Consumer Healthcare Products Association
Non-profit representing the makers of over-the-counter medicines & nutritional supplements
SENATEHOUSE OF REPRESENTATIVES
$30,000
Jul 22, 2019
SECOND QUARTER REPORT
DJO Incorporated
Provider of high-quality, orthopedic devices.
SENATEHOUSE OF REPRESENTATIVES
$30,000
Jul 22, 2019
SECOND QUARTER REPORT
Global Blood Therapeutics
Biopharmaceutical Research Company.
SENATEHOUSE OF REPRESENTATIVES
$30,000
Jul 22, 2019
SECOND QUARTER REPORT
UNITED SERVICES AUTOMOBILE ASSOCIATION (USAA)
Insurance and Financial Institution
SENATEHOUSE OF REPRESENTATIVES
$30,000
Oct 21, 2019
THIRD QUARTER REPORT
CALIFORNIA LIFE SCIENCES ASSOCIATION
A public policy research and advocacy organization for California's biomedical industry.
SENATEHOUSE OF REPRESENTATIVES
$30,000
Oct 21, 2019
THIRD QUARTER REPORT
Consumer Healthcare Products Association
Non-profit representing the makers of over-the-counter medicines & nutritional supplements
SENATEHOUSE OF REPRESENTATIVES
$30,000
Oct 21, 2019
THIRD QUARTER REPORT
DJO Incorporated
Provider of high-quality, orthopedic devices.
SENATEHOUSE OF REPRESENTATIVES
$30,000
Oct 21, 2019
THIRD QUARTER REPORT
Global Blood Therapeutics
Biopharmaceutical Research Company.
SENATEHOUSE OF REPRESENTATIVES
$30,000
Oct 21, 2019
THIRD QUARTER REPORT
Moderna, Inc.
Biotechnology company.
SENATEHOUSE OF REPRESENTATIVES
$30,000
Oct 21, 2019
THIRD QUARTER REPORT
UNITED SERVICES AUTOMOBILE ASSOCIATION (USAA)
Insurance and Financial Institution
SENATEHOUSE OF REPRESENTATIVES
$30,000
Jan 21, 2020
FOURTH QUARTER REPORT
CALIFORNIA LIFE SCIENCES ASSOCIATION
A public policy research and advocacy organization for California's biomedical industry.
SENATEHOUSE OF REPRESENTATIVES
$30,000
Jan 21, 2020
FOURTH QUARTER TERMINATION
Consumer Healthcare Products Association
Non-profit representing the makers of over-the-counter medicines & nutritional supplements
SENATEHOUSE OF REPRESENTATIVES
$30,000
Jan 21, 2020
FOURTH QUARTER REPORT
DJO Incorporated
Provider of high-quality, orthopedic devices.
SENATEHOUSE OF REPRESENTATIVES
$30,000
Jan 21, 2020
FOURTH QUARTER REPORT
Global Blood Therapeutics
Biopharmaceutical Research Company.
SENATEHOUSE OF REPRESENTATIVES
$30,000
Jan 21, 2020
FOURTH QUARTER REPORT
UNITED SERVICES AUTOMOBILE ASSOCIATION (USAA)
Insurance and Financial Institution
SENATEHOUSE OF REPRESENTATIVES
$30,000
Jan 21, 2020
FOURTH QUARTER REPORT
INCYTE CORPORATION
​Biopharmaceutical Company.
SENATEHOUSE OF REPRESENTATIVES
$30,000
Apr 20, 2020
FIRST QUARTER REPORT
CALIFORNIA LIFE SCIENCES ASSOCIATION
A public policy research and advocacy organization for California's biomedical industry.
SENATEHOUSE OF REPRESENTATIVES
$30,000
Apr 20, 2020
FIRST QUARTER REPORT
DJO Incorporated
Provider of high-quality, orthopedic devices.
SENATEHOUSE OF REPRESENTATIVES
$30,000
Apr 20, 2020
FIRST QUARTER REPORT
Global Blood Therapeutics
Biopharmaceutical Research Company.
SENATEHOUSE OF REPRESENTATIVES
$30,000
Apr 20, 2020
FIRST QUARTER REPORT
INCYTE CORPORATION
​Biopharmaceutical Company.
SENATEHOUSE OF REPRESENTATIVES
$30,000
Apr 20, 2020
FIRST QUARTER REPORT
UNITED SERVICES AUTOMOBILE ASSOCIATION (USAA)
Insurance and Financial Institution
SENATEHOUSE OF REPRESENTATIVES
$20,000
Jan 22, 2019
FOURTH QUARTER REPORT
23andMe, Inc.
A genetics company.
SENATEHOUSE OF REPRESENTATIVES
$20,000
Apr 22, 2019
FIRST QUARTER REPORT
23andMe, Inc.
A genetics company.
SENATEHOUSE OF REPRESENTATIVES
$20,000
Jul 22, 2019
SECOND QUARTER REPORT
23andMe, Inc.
A genetics company.
SENATEHOUSE OF REPRESENTATIVES
$20,000
Oct 21, 2019
THIRD QUARTER REPORT
23andMe, Inc.
A genetics company.
SENATEHOUSE OF REPRESENTATIVES
$20,000
Oct 21, 2019
THIRD QUARTER TERMINATION
TESARO, Inc.
Biopharmaceutical company.
SENATEHOUSE OF REPRESENTATIVES
$20,000
Jan 21, 2020
FOURTH QUARTER REPORT
23andMe, Inc.
A genetics company.
SENATEHOUSE OF REPRESENTATIVES
$20,000
Apr 20, 2020
FIRST QUARTER REPORT
23andMe, Inc.
A genetics company.
SENATEHOUSE OF REPRESENTATIVES
$10,000
Jul 22, 2019
SECOND QUARTER REPORT
Moderna, Inc.
Biotechnology company.
SENATEHOUSE OF REPRESENTATIVES
$10,000
Apr 20, 2020
FIRST QUARTER REPORT
Moderna, Inc.
Biotechnology company.
SENATEHOUSE OF REPRESENTATIVES
$0
Jan 18, 2019
REGISTRATION
Global Blood Therapeutics
Biopharmaceutical Research Company.
SENATEHOUSE OF REPRESENTATIVES
$0
Feb 7, 2019
REGISTRATION
TESARO, Inc.
Biopharmaceutical company.
SENATEHOUSE OF REPRESENTATIVES
$0
Feb 14, 2019
REGISTRATION
Gilead Sciences, Inc.
American biotechnology company that researches, develops and commercializes drugs.
SENATEHOUSE OF REPRESENTATIVES
$0
Jul 22, 2019
SECOND QUARTER TERMINATION
McKesson Corporation
Health care services company
SENATEHOUSE OF REPRESENTATIVES
$0
Jun 28, 2019
REGISTRATION
Moderna, Inc.
Biotechnology company.
SENATEHOUSE OF REPRESENTATIVES
$0
Dec 17, 2019
REGISTRATION
​Incyte Corporation
​Biopharmaceutical Company.
SENATEHOUSE OF REPRESENTATIVES
$0
Jan 21, 2020
FOURTH QUARTER TERMINATION (NO ACTIVITY)
Moderna, Inc.
Biotechnology company.
SENATEHOUSE OF REPRESENTATIVES
$0
Apr 16, 2020
REGISTRATION AMENDMENT
Moderna, Inc.
Biotechnology company.
SENATEHOUSE OF REPRESENTATIVES
$0
Jun 4, 2020
REGISTRATION
Secure Identity, LLC
​Identity Management and Security.
SENATEHOUSE OF REPRESENTATIVES